These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19605506)

  • 1. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.
    Hahn NM; Zon RT; Yu M; Ademuyiwa FO; Jones T; Dugan W; Whalen C; Shanmugam R; Skaar T; Sweeney CJ
    Ann Oncol; 2009 Dec; 20(12):1971-6. PubMed ID: 19605506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.
    Caffo O; Fratino L; Barbieri R; Perin A; Martini T; Sava T; Segati R; Vaccher E; Bernardo Bassan F; Veccia A; Pappagallo G; Galligioni E
    Urol Oncol; 2013 Feb; 31(2):180-6. PubMed ID: 21803618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
    Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
    Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
    Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
    J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
    Wei GL; Huang XE; Huo JG; Wang XN; Tang JH
    Asian Pac J Cancer Prev; 2013; 14(5):2703-6. PubMed ID: 23803018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
    Chen JS; Chao Y; Bang YJ; Roca E; Chung HC; Palazzo F; Kim YH; Myrand SP; Mullaney BP; Shen LJ; Linn C
    Anticancer Drugs; 2010 Sep; 21(8):777-84. PubMed ID: 20634689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients.
    Wu YL; Sun Y; Zhou CC; Zhang L; Yu SY; Ma SL; Han LL; Zhang XQ; Orlando M
    Chin Med J (Engl); 2013; 126(24):4624-8. PubMed ID: 24342300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of pemetrexed in patients with metastatic renal cancer.
    Thödtmann R; Sauter T; Weinknecht S; Weissbach L; Blatter J; Ohnmacht U; Hanauske A
    Invest New Drugs; 2003 Aug; 21(3):353-8. PubMed ID: 14578684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
    Cohen MH; Johnson JR; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005; 10(6):363-8. PubMed ID: 15967829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.
    Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G
    Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
    Miller KD; Picus J; Blanke C; John W; Clark J; Shulman LN; Thornton D; Rowinsky E; Loehrer PJ
    Ann Oncol; 2000 Jan; 11(1):101-3. PubMed ID: 10690396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.